TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Key Inclusion Criteria:~* Signed written informed consent~* 40 - 80 years of age~* Clinical history of COPD with airflow limitation that is not fully reversible~* Females of non-child bearing potential or females of child bearing potential with negative pregnancy test and acceptable contraceptive methods~* Current/former smokers with at least a 10 pack-year history of cigarette smoking~* A measured post-bronchodilator FEV1/FVC ratio of \< or = 0.70~* A measured post-bronchodilator FEV1 \> or = 750ml or 30% predicted and \< or = 80% of predicted normal values~* Able to change COPD treatment as required by protocol~Key Exclusion Criteria:~* Women who are pregnant or lactating~* Primary diagnosis of asthma~* Alpha-1 antitrypsin deficiency as the cause of COPD~* Active pulmonary diseases~* Prior lung volume reduction surgery~* Abnormal chest X-ray not due to the presence of COPD~* Hospitalized due to poorly controlled COPD within 3 months of Screening~* Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)~* Cancer that has not been in complete remission for at least 5 years~* Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives~Other inclusion/exclusion criteria as defined in the protocol

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PT003 (Dose 1) (Type: EXPERIMENTAL): PT003 MDI Dose 1
- PT003 (Dose 2) (Type: EXPERIMENTAL): PT003 MDI Dose 2
- PT003 (Dose 3) (Type: EXPERIMENTAL): PT003 MDI Dose 3
- PT003 (Dose 4) (Type: EXPERIMENTAL): PT003 MDI Dose 4
- PT003 (Dose 5) (Type: EXPERIMENTAL): PT003 MDI Dose 5
- PT001 (Type: EXPERIMENTAL): PT001 MDI
- PT005 (Type: EXPERIMENTAL): PT005 MDI
- Spiriva® Handihaler® (Type: ACTIVE_COMPARATOR): Tiotropium Bromide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed NSCLC, locally advanced and metastatic disease stage IIIB and IV. Evidence of disease progression after one or two cytotoxic treatment regimens which should have included a platinum agent.~2. Complete recovery from prior chemotherapy side effects to \< Grade 2.~3. At least one unidimensional measurable lesion meeting RECIST criteria.~4. ECOG PS 0-2.~5. Age \> 18 years.~6. Adequate organ function, including:~   * Adequate bone marrow reserve: ANC \> 1.5 x 109/L, platelets \> 100 x 109/L.~  * Hepatic: bilirubin \<1.5 x ULN, AP, ALT, AST \< 1.5 x ULN AP, ALT, and AST \<5 x ULN is acceptable if the liver has tumor involvement~  * Renal: calculated creatinin clearance \> 40 ml/min based on the Cockcroft-Gault formula.~7. Estimated life expectancy \>12 weeks.~8. Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate. Female patients with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment.~9. Signed informed consent.~10. Patient compliance and geographical proximity that allow adequate follow up.~Exclusion Criteria:~1. Pregnant or lactating women.~2. Patients with medical risks because of non-malignant disease as well as those with active uncontrolled infection.~3. Documented brain metastases unless the patient has completed local therapy for central nervous system metastases and has been off corticosteroids for at least two weeks before enrollment.~4. Previous treatment with an EGFR-TKI, or in non-squamous histology earlier treatment with pemetrexed and in squamous earlier treatment with docetaxel.~5. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (5 day period for long-acting agents such as piroxicam).~6. Inability or unwillingness to take folic acid, vitamin B-12 supplementation or dexamethasone.~7. Concomitant treatment with any other experimental drug under investigation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Erlotinib plus docetaxel (squamous cell NSCLC) or pemetrexed (non-squamous cell NSCLC)
- 2 (Type: ACTIVE_COMPARATOR): Erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin Peripheral Neuropathic Pain Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of peripheral neuropathic pain syndrome, including diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN), or post-traumatic neuropathic pain (including post-surgical), confirmed by a qualified pain specialist.~* Subjects must have completed at least 4 daily pain diaries during the 7 days prior to Visit 2 and have an average pain score of ≥4 over the 7 days prior to Visit 2 (randomization).~Exclusion Criteria:~* Neurologic disorders unrelated to DPN, PHN, or post-traumatic neuropathic pain (including post-surgical), that may confuse or confound the assessment of neuropathic pain.~* Presence of any severe pain associated with conditions other than DPN, PHN, or post-traumatic neuropathic pain (including post-surgical) that may confound the assessment or self evaluation of the pain due to DPN, PHN, or post-traumatic neuropathic pain (including post-surgical).~* Creatinine clearance \< 30 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation in Appendix E). Maximum dose for subjects with creatinine clearance of 30 to 60 mL/min is 300 mg/day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of lymphoplasmacytic lymphoma including patients with Waldenstrom's macroglobulinemia~* Adequate organ function: ANC \> 500/ul; PLT \> 25,000/ul; serum creatinine \< 2.5; serum total bilirubin and SGOT \< 2.5 times the upper normal limit.~* Age greater than 18 years~* Life expectancy of 6 months or greater~* ECOG performance status of 0-2~Exclusion Criteria:~* Chemotherapy, steroid therapy, or radiation therapy within 21 days of study entry.~* Prior Campath-1H or monoclonal antibody therapy within 3 months of study entry.~* Pregnant women~* Serious co-morbid disease, uncontrolled bacterial, fungal, or viral infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Campath-1H (Type: EXPERIMENTAL): 30 mg IV three times a week, 6-12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent before any study related procedure~* Male and female patients age 18 years or older at time of enrollment~* Diagnosis of intestinal obstruction of malignant origin~* In case of peritoneal carcinomatosis, confirmation by CT or MRI scan within the 3 months preceding the inclusion in the study~* Confirmed as inoperable after surgical advice~* Patient with a nasogastric tube OR presenting with 3 or more episodes of vomiting / 24h in the last 48 hours~* Estimated life expectancy 1 month or more~Exclusion Criteria:~* Operable obstruction or subobstruction~* Bowel obstruction due to a non-malignant cause~* Signs of bowel perforation~* Prior treatment with somatostatin or any other analogue within the previous 60 days~* A known hypersensitivity to any of the study treatments or related compounds~* Previous participation in this study~* Is likely to require treatment during the study with drugs that are not permitted by the study protocol~* Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the subject's safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lanreotide Autogel (Type: EXPERIMENTAL): 120mg administered via deep subcutaneous injection at Day 0 and Day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Estimate of the Activity and the Forecast of the Lupus Disease of the Adult by a Transcriptomic Score (STUDY LU-PUCE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Lupus disease diagnosed for lupus disease arm~* Signed assent~Exclusion Criteria:~* non-compliance~* pregnancy~* persons without social coverage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lupus disease (Type: EXPERIMENTAL): None
- Healthy witnesses (Type: ACTIVE_COMPARATOR): None
- Healthy witnesses with an other auto-immune disease (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin and Diastolic Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men or postmenopausal women aged between 40 and 65 years old~* normal fasting blood glucose (\<100 mg/dL) and glucose tolerance test (\<140 mg/dL)~* waist circumference \< 102 cm (men) or \< 88cm (women)~* triglycerides \<150 mg/dL, LDL cholesterol ≤ 160 mg/dl~* creatinine \<1.2 mg/dL, sinus rhythm~* the presence of grade 1 or 2 of DD with an ejection fraction of left ventricle \> 55%~* absence of myocardial ischemia during dobutamine stress echocardiography~Exclusion Criteria:~* thyroid dysfunction~* acute or chronic liver disease~* regular use of 3 or more antihypertensive drugs~* secondary hypertension~* symptoms or history of atherosclerotic disease~* valvular dysfunction~* LVH 14 and use of statins in the last 6 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Simvastatin (Type: EXPERIMENTAL): Simvastatin 80 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* be willing and able to sign consent forms;~* be eligible for medical abortion according to clinician's assessment;~* be willing to undergo a surgical completion if necessary;~* have ready and easy access to a telephone and emergency transportation;~* speak English, Spanish, or have a translator available to translate for all study procedures; and,~* agree to comply with the study procedures and visit schedule.~Exclusion Criteria:~* Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;~* IUD in place;~* Chronic renal failure;~* Concurrent long-term corticosteroid therapy;~* History of allergy to mifepristone, misoprostol or other prostaglandin;~* Hemorrhagic disorders or concurrent anticoagulant therapy;~* Inherited porphyrias; or~* Other serious physical or mental health conditions.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhanced Medical Rehabilitation in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 65 and older~* Admitted to a skilled nursing facility for post-acute care from PT and OT for 2 weeks or more.~Exclusion Criteria:~* Language, visual or hearing barriers to participation~* Medical illness preventing study participation or accurate data collection~* Moderate-severe dementia (demonstrated by chart diagnosis and/or short blessed score greater than 13)~* Progressive neurological condition such that recovery of function is not feasible~* Patient did not have the ability to walk prior to hospitalization (e.g. paraplegic)~* Schizophrenia or other chronic or current psychotic disorder.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care Rehabilitation (Type: ACTIVE_COMPARATOR): None
- Enhanced Medical Rehabilitation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Probing depth ≥7 mm at baseline~2. Presence of ≥4 mm vertical bone defect with at least 1 bony wall after surgical debridement.~3. Adequate keratinized tissue to permit complete tissue coverage of defect.~4. Radiographic base of defect ≥3 mm coronal to the apex of the tooth.~Exclusion Criteria:~1. Failure to maintain adequate oral hygiene (plaque index\>2)~2. Pregnant and lactating women~3. History of oral cancer or HIV~4. Periodontal surgery on treatment-targeted tooth within the last year.~5. Tooth mobility greater than grade II.~6. Study tooth exhibiting a class III furacation defect~7. Localized aggressive periodontitis~8. Radiographic signs of untreated acute infection at the surgical site~9. Recent history of smoking more than 20 cigarettes/day~10. Known allergy to E.coli-derived products~11. Using an investigational therapy within the past 30 days.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Drug Group (Type: EXPERIMENTAL): PERIOGEN
- Control group (Type: ACTIVE_COMPARATOR): Beta TCP alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of any subtype of ADHD~* Normal findings on physical exam, laboratory studies, vital signs, and ECG~* Weight = 60 kgs or less~* Able to complete study procedures and swallow capsules;~* Willing to commit to the entire visit schedule~* Off treatment or have been discontinued from their previous medication for two weeks.~Exclusion Criteria:~* Psychiatric comorbidity except Oppositional Defiant Disorder \[ODD\], Simple Phobia, and dysthymia (unless ongoing medication treatment is required);~* Currently a suicide risk, has previously made a suicide attempt or has a prior history of suicidal behavior;~* Has failed treatment with an adequate trial of an alpha-2 adrenergic agonist;~* Known or suspected allergy, hypersensitivity, or clinically significant intolerance to guanfacine hydrochloride.~Children may not:~* be treated with systemic medication for a medical or psychiatric illness that have CNS effects or affect cognitive function;~* have a known history or presence of structural cardiac abnormalities, exercise-related cardiac events, or clinically significant bradycardia;~* have orthostatic hypotension or a known history of hypertension;~* have an abnormal ECG that is deemed clinically significant;~* have a history of alcohol or other substance abuse or dependence within the last 6 months;~* use any medications that affect BP or heart rate (excluding the subject's current ADHD medication at screening);~* use another investigational medicinal product or participation in a clinical study within 30 days prior to the baseline visit;~* be significantly overweight based on Center for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts;~* have body weight of less than 25kg;~* have a clinically important abnormality on urine drug and alcohol screen (excluding the subject's current ADHD stimulant, if applicable);~* be female and currently pregnant or lactating;~* have symptoms indicative of a primary sleep disorder.~* have braces or other metal permanently placed within their body.~* be too anxious to tolerate the fMRI procedure, or be claustrophobic.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- guanfacine hydrochloride XR (Type: EXPERIMENTAL): Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily
- Placebo Group (Type: PLACEBO_COMPARATOR): Flexible dose titration of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 21 to 75~* Biopsy-confirmed NASH with fibrosis stage F2 or F3 per NASH CRN System and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation.~  * Qualifying biopsy must be either within 6 months of screening visit or obtained during screening period~Key Exclusion Criteria:~* Have poorly controlled high blood pressure~* Have type 1 diabetes or poorly controlled type 2 diabetes.~* History of cirrhosis or evidence of cirrhosis by clinical, imaging or liver biopsy evaluation~* Are planning to try to lose weight during the conduct of the study.~* Have a BMI \<25 kg/m2~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BIO89-100 - 15 mg once weekly (QW) (Type: EXPERIMENTAL): BIO89-100 - 15 mg QW
- BIO89-100 - 30 mg QW (Type: EXPERIMENTAL): BIO89-100 - 30 mg QW
- BIO89-100 - 44 mg once every 2 weeks (Q2W) (Type: EXPERIMENTAL): BIO89-100 - 44 mg Q2W
- Placebo QW (Type: PLACEBO_COMPARATOR): Placebo QW
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Placebo Q2W
- Placebo QW (Main study)/ BIO89-100 - 30 mg QW (Extension) (Type: EXPERIMENTAL): Placebo QW (Main study)/ BIO89-100 - 30 mg QW (Extension)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Major depressive disorder based on DSM-IV TR criteria~* Age 18-50~* Hamilton Depression Rating scale \>=22~* Signing the informed consent form~* Citalopram be the drug of choice for the patient irrespective of other eligibility criteria~Exclusion Criteria:~* Problems in other Axes~* Pregnancy and lactation~* Serious or life threatening disease~* taking other antidepressant in the recent month or Electroconvulsive shock in the recent two months, and taking other psychotropic agents~* Diabetes controlled with drugs or insulin (patients with only lifestyle interventions will be included), Liver disease, Congestive heart failure Class III and IV~* Metabolic syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone+Citalopram+Chlordiazepoxide (Type: ACTIVE_COMPARATOR): Pioglitazone 15 mg Q12h will be given to the patients in active comparator group for 6 weeks. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.Chlordiazepoxide 10 mg/day for first three weeks
- Placebo+ Citalopram+ Chlordiazepoxide (Type: PLACEBO_COMPARATOR): Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete